Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified

Annals of Hematology

Volumn 94, Issue 10, 2015, Pages 1655-1665

  Hwang, Hee Sang ^a   Yoon, Dok Hyun ^a   Suh, Cheolwon ^a   Huh, Jooryung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Asians; Body mass index; Diffuse large B cell lymphoma; Obesity

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ASIAN; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL; UNDERWEIGHT; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT ANALYSIS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; COHORT STUDIES; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941004911     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2438-4     Document Type: Article

References (43)

1. Visscher TL, Seidell JC (2001) The public health impact of obesity. Annu Rev Public Health 22:355–375. doi:10.1146/annurev.publhealth.22.1.355
2. World Health Organization. BMI classification. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed 14 May 2015
3. WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157–163. doi:10.1016/S0140-6736(03)15268-3
4. Oh SW, Shin SA, Yun YH, Yoo T, Huh BY (2004) Cut-off point of BMI and obesity-related comorbidities and mortality in middle-aged Koreans. Obes Res 12:2031–2040. doi:10.1038/oby.2004.254
5. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578. doi:10.1016/S0140-6736(08)60269-X
6. Jee SH, Yun JE, Park EJ et al (2008) Body mass index and cancer risk in Korean men and women. Int J Cancer 123:1892–1896. doi:10.1002/ijc.23719
7. Chang ET, Hjalgrim H, Smedby KE et al (2005) Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst 97:210–218. doi:10.1093/jnci/dji012
8. Chiu BC, Soni L, Gapstur SM, Fought AJ, Evens AM, Weisenburger DD (2007) Obesity and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control 18:677–685. doi:10.1007/s10552-007-9013-9
9. Kanda J, Matsuo K, Suzuki T et al (2010) Association between obesity and the risk of malignant lymphoma in Japanese: a case-control study. Int J Cancer 126:2416–2425. doi:10.1002/ijc.24955
10. Jones JA, Fayad LE, Elting LS, Rodriguez MA (2010) Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 51:1649–1657. doi:10.3109/10428194.2010.494315
11. Carson KR, Bartlett NL, McDonald JR et al (2012) Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol 30:3217–3222. doi:10.1200/JCO.2011.39.2100
12. Park S, Han B, Cho JW et al (2014) Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer 66:225–233. doi:10.1080/01635581.2014.867065
13. Weiss L, Melchardt T, Habringer S et al (2014) Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol 25:171–176. doi:10.1093/annonc/mdt481
14. Hong F, Habermann TM, Gordon LI et al (2014) The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol 25:669–674. doi:10.1093/annonc/mdt594
15. Stein H, Chan JKC, Warnke RA et al (2008) Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 233–237
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
17. Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636
18. Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16:2780–2795
19. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282. doi:10.1182/blood-2003-05-1545
20. Hwang HS, Park CS, Yoon DH, Suh C, Huh J (2014) High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol 38:1046–1057. doi:10.1097/PAS.0000000000000211
21. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
22. Oh SW (2011) Obesity and metabolic syndrome in Korea. Diabetes Metab J 35:561–566. doi:10.4093/dmj.2011.35.6.561
23. Kim MK, Lee WY, Kang JH et al (2014) 2014 clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab (Seoul) 29:405–409. doi:10.3803/EnM.2014.29.4.405
24. Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977
25. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 22:4302–4311. doi:10.1200/JCO.2004.03.213
26. Harrell FE (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New York
27. Atkinson AC (1980) A note on the generalized information criterion for choice of a model. Biometrika 67:413–418
28. Therneau TM, Grambsch PM, Fleming TR (1990) Martingale-based residuals for survival models. Biometrika 77:147–160. doi:10.1093/biomet/77.1.147
29. Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis. Part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. Br J Cancer 89:605–611. doi:10.1038/sj.bjc.6601120
30. Lichtman MA (2010) Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 15:1083–1101. doi:10.1634/theoncologist.2010-0206
31. Murphy F, Kroll ME, Pirie K, Reeves G, Green J, Beral V (2013) Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer 108:2390–2398. doi:10.1038/bjc.2013.159
32. Leo QJ, Ollberding NJ, Wilkens LR et al (2014) Obesity and non-Hodgkin lymphoma survival in an ethnically diverse population: the Multiethnic Cohort study. Cancer Causes Control 25:1449–1459. doi:10.1007/s10552-014-0447-6
33. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6:1321–1327
34. Landgren O, Andren H, Nilsson B, Ekbom A, Bjorkholm M (2005) Risk profile and outcome in Hodgkin’s lymphoma: is obesity beneficial? Ann Oncol 16:838–840. doi:10.1093/annonc/mdi145
35. Sparreboom A, Wolff AC, Mathijssen RH et al (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707–4713. doi:10.1200/JCO.2007.11.2938
36. Muller C, Murawski N, Wiesen MH et al (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119:3276–3284. doi:10.1182/blood-2011-09-380949
37. Wong AL, Seng KY, Ong EM et al (2014) Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat 144:143–152. doi:10.1007/s10549-014-2843-8
38. Camus V, Lanic H, Kraut J et al (2014) Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol 93:9–18. doi:10.1111/ejh.12285
39. Lanic H, Kraut-Tauzia J, Modzelewski R et al (2014) Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55:817–823. doi:10.3109/10428194.2013.816421
40. Sarkozy C, Camus V, Tilly H, Salles G, Jardin F (2015) Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era. Leuk Lymphoma: 1-10. doi:10.3109/10428194.2014.979412
41. Chang CM, Wang SS, Dave BJ et al (2011) Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study. Int J Cancer 129:938–947. doi:10.1002/ijc.25717
42. Kanda J, Matsuo K, Inoue M et al (2010) Association of anthropometric characteristics with the risk of malignant lymphoma and plasma cell myeloma in a Japanese population: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 19:1623–1631. doi:10.1158/1055-9965.EPI-10-0171
43. Patel AV, Diver WR, Teras LR, Birmann BM, Gapstur SM (2013) Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma 54:1221–1227. doi:10.3109/10428194.2012.742523